City
Epaper

WHO flags three contaminated cough syrups in India, including Coldrif

By IANS | Updated: October 14, 2025 09:30 IST

New Delhi, Oct 14 The World Health Organisation (WHO) has identified three adulterated syrups manufactured in India, including ...

Open in App

New Delhi, Oct 14 The World Health Organisation (WHO) has identified three adulterated syrups manufactured in India, including the infamous Coldrif cough syrup, and has urged authorities worldwide to report to the agency if any of these products are detected in their respective countries.

The development comes weeks after the deaths of several children in Madhya Pradesh, linked to the consumption of adulterated cough syrup.

Among the three contaminated syrups flagged by WHO is Coldrif, which recently triggered widespread outrage following the children's deaths.

The global health body has identified specific batches of Coldrif from Sresan Pharmaceuticals, Respifresh TR from Rednex Pharmaceuticals, and ReLife from Shape Pharma as the affected medicines.

WHO warned that the identified syrups could cause severe and potentially life-threatening illnesses.

The Coldrif syrup, manufactured in Tamil Nadu, sparked major alarm after it was found to be dangerously contaminated with the toxic chemical diethylene glycol (DEG).

Tests revealed DEG concentrations exceeding 48 per cent -- an alarming figure far above the permissible limit of 0.1 per cent.

Following this, Sresan Pharmaceuticals had its manufacturing license revoked, and its owner, G. Ranganathan, was arrested.

The authorities also ordered a comprehensive inspection of other drug manufacturing companies across the southern state to identify potential lapses in quality control.

The deaths of children in Madhya Pradesh prompted the Central government to issue an advisory to all states and union territories, urging extreme caution in the prescription of cough syrups for children.

The advisory specifically stated that such medications should not be prescribed or dispensed to children below two years of age and are generally not recommended for those under five.

Health officials have emphasised that the incident highlights the urgent need for stricter regulatory oversight of pharmaceutical manufacturing in the country to prevent similar tragedies.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

Entertainment“Actually Mujhe Bahut Zyada Support Mila Hai With 2 Studios in India That Is Balaji and Dharma,” Guneet Monga on Industry Backing

TechnologyHSBC launches 'Digital Merchant Services' in India for e-commerce merchants

TechnologyInfosys wins UK NHS contract worth 1.2 billion pounds to modernise workforce solution

HealthInfosys wins UK NHS contract worth 1.2 billion pounds to modernise workforce solution

BusinessHSBC launches 'Digital Merchant Services' in India for e-commerce merchants

National Realted Stories

NationalBJP defends ECI's directive on burqa-clad voters, slams SP for calling it 'undemocratic'

NationalSC adjourns hearing on plea challenging Sonam Wangchuk's detention

NationalJal Shakti Ministry announces Rs 15,000 monthly media internship for college students

NationalIn a society steeped in caste hierarchy, progress is impossible: Karnataka CM

NationalLiquor scam: SIT conducts searches at places linked to YSRCP MP